Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
This article was originally published in The Pink Sheet Daily
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.
You may also be interested in...
Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
In an interview, the PBM's chief medical officer discusses outcomes-based contracts, comments on whether the drug pricing debate will be impacted by slowing growth in drug spending, and notes an upcoming focus at the PBM on controlling diabetes drug costs